Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Stemline Therapeutics Inc Announces Exercise Of Option To Purchase Additional Shares


Thursday, 23 May 2013 08:30am EDT 

Stemline Therapeutics Inc announced that the underwriters have exercised in full their option to purchase an additional 620,689 shares of common stock. The option to purchase additional shares is being exercised in connection with Stemline's previously announced public offering of 4,137,931 shares of common stock at a public offering price of $14.50 per share. As a result of the exercise of the option, the total gross proceeds to Stemline from the offering are expected to be approximately $69,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. The closing of the option to purchase additional shares is expected to occur on or about May 28, 2013. 

Company Quote

14.79
0.38 +2.64%
26 Nov 2014